

Olle Ringden

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5311376/olle-ringden-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

370
papers

31,498
citations

80
h-index

169
g-index

375
ext. papers

34,192
ext. citations

4.2
avg, IF

6.63
L-index

#	Paper	IF	Citations
370	Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome.. <i>Frontiers in Immunology</i> , 2022 , 13, 839844	8.4	2
369	Expanded Hemodialysis Therapy Ameliorates Uremia-Induced Systemic Microinflammation and Endothelial Dysfunction by Modulating VEGF, TNF- α and AP-1 Signaling. <i>Frontiers in Immunology</i> , 2021 , 12, 774052	8.4	2
368	Conquering the cytokine storm in COVID-19-induced ARDS using placenta-derived decidual stromal cells. <i>Journal of Cellular and Molecular Medicine</i> , 2021 , 25, 10554-10564	5.6	4
367	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2108-2117	4.4	1
366	Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft-versus-host disease prophylaxis. <i>Oral Diseases</i> , 2021 , 27, 1217-1225	3.5	2
365	Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care. <i>International Journal of Hematology</i> , 2021 , 113, 712-722	2.3	1
364	Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2021 , 39, 2397-2409	2.2	7
363	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 923.e1-923.e12		1
362	Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 993.e1-993.e1		1
361	Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021 ,	7.8	3
360	Can we prevent or treat graft-versus-host disease with cellular-therapy?. <i>Blood Reviews</i> , 2020 , 43, 100669	11.1	9
359	Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical and Translational Science</i> , 2020 , 13, 293-300	4.9	3
358	Treatment of radiculomyelopathy in two patients with placenta-derived decidual stromal cells. <i>International Journal of Hematology</i> , 2020 , 111, 591-594	2.3	2
357	Mesenchymal Stromal Cells in Pediatric Hematopoietic Cell Transplantation a Review and a Pilot Study in Children Treated With Decidual Stromal Cells for Acute Graft-versus-Host Disease. <i>Frontiers in Immunology</i> , 2020 , 11, 567210	8.4	6
356	Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines. <i>Trends in Molecular Medicine</i> , 2019 , 25, 149-163	11.5	160
355	Long-Term Follow-Up of a Pilot Study Using Placenta-Derived Decidual Stromal Cells for Severe Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1965-1969	4.7	7
354	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1975-1983	4.7	32

353	Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 73-85	4.7	25
352	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019 , 3, 1441-1449	7.8	7
351	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019 , 3, 1826-1836	7.8	50
350	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. <i>Blood Advances</i> , 2019 , 3, 3123-3131	7.8	18
349	The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Inherited Diseases Is Influenced by HLA Match, Year of Transplantation, and Immunized Female Donor. <i>Transplantation</i> , 2019 , 103, 1247-1252	1.8	1
348	Preclinical Toxicity Evaluation of Clinical Grade Placenta-Derived Decidua Stromal Cells. <i>Frontiers in Immunology</i> , 2019 , 10, 2685	8.4	12
347	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT. <i>British Journal of Haematology</i> , 2019 , 184, 782-787	4.5	37
346	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 270-278	4.7	14
345	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 362-368	4.7	24
344	Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT. <i>European Journal of Cancer</i> , 2018 , 96, 73-81	7.5	24
343	Placenta-Derived Decidua Stromal Cells for Treatment of Severe Acute Graft-Versus-Host Disease. <i>Stem Cells Translational Medicine</i> , 2018 , 7, 325-331	6.9	50
342	Tumour necrosis factor-alpha in uraemic serum promotes osteoblastic transition and calcification of vascular smooth muscle cells via extracellular signal-regulated kinases and activator protein 1/c-FOS-mediated induction of interleukin 6 expression. <i>Nephrology Dialysis Transplantation</i> , 2018 , 33, 574-585	4.3	38
341	Placenta-Derived Decidua Stromal Cells for Hemorrhagic Cystitis after Stem Cell Transplantation. <i>Acta Haematologica</i> , 2018 , 139, 106-114	2.7	16
340	Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting. <i>Medical Oncology</i> , 2018 , 35, 79	3.7	8
339	What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?. <i>Journal of Internal Medicine</i> , 2018 , 283, 166-177	10.8	7
338	Cytomegalovirus-Specific CD8+ T-Cells With Different T-Cell Receptor Affinities Segregate T-Cell Phenotypes and Correlate With Chronic Graft-Versus-Host Disease in Patients Post-Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2018 , 9, 760	8.4	8
337	Long-term outcome in patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2018 , 107, 478-485	2.3	8
336	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 521-528	4.7	19

335	Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma. <i>Bone Marrow Transplantation</i> , 2018 , 53, 213-218	4.4	6
334	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. <i>Blood Advances</i> , 2018 , 2, 2922-2936	7.8	17
333	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. <i>Blood Advances</i> , 2018 , 2, 1022-1031	7.8	8
332	Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 1327-1334 ²⁷	4.7	27
331	A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer. <i>Journal of Immunotherapy</i> , 2017 , 40, 132-139	5	4
330	Successful treatment with placenta-derived decidual stromal cells in a pediatric patient with life-threatening acute gastrointestinal graft-versus-host disease. <i>Pediatric Transplantation</i> , 2017 , 21, e12990	1.8	2
329	GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. <i>Bone Marrow Transplantation</i> , 2017 , 52, 400-408	4.4	32
328	Photochemotherapy and Graft-versus-Leukemia Reaction in Acute Leukemia: Tumor Immunity and Survival Are Dependent on Timing of Photochemotherapy of the Skin. <i>Dermatology</i> , 2017 , 233, 303-313	4.4	
327	Frontline Science: Placenta-derived decidual stromal cells alter IL-2R expression and signaling in alloantigen-activated T cells. <i>Journal of Leukocyte Biology</i> , 2017 , 101, 623-632	6.5	6
326	Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2017 , 92, 42-49	7.1	38
325	Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT. <i>British Journal of Haematology</i> , 2017 , 176, 431-439	4.5	20
324	Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis. <i>Frontiers in Immunology</i> , 2017 , 8, 795	8.4	27
323	Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings?. <i>Leukemia</i> , 2016 , 30, 447-55	10.7	62
322	Photochemotherapy of Cutaneous Graft-versus-Host Disease May Reduce Concomitant Visceral Disease. <i>Dermatology</i> , 2016 , 232, 453-63	4.4	1
321	A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2016 , 101, 1417-1425	6.6	41
320	Cryopreserved or Fresh Mesenchymal Stromal Cells: Only a Matter of Taste or Key to Unleash the Full Clinical Potential of MSC Therapy?. <i>Advances in Experimental Medicine and Biology</i> , 2016 , 951, 77-98	3.6	81
319	Intra-arterial Administration of Placenta-Derived Decidual Stromal Cells to the Superior Mesenteric Artery in the Rabbit: Distribution of Cells, Feasibility, and Safety. <i>Cell Transplantation</i> , 2016 , 25, 401-10	4	7
318	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 248-257	4.7	27

317	Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. <i>Lancet Haematology,the</i> , 2016 , 3, e45-52	14.6	117
316	Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 676-681	4.7	8
315	Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning. <i>Oncotarget</i> , 2016 , 7, 30230-40	3.3	8
314	Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Human C1q Deficiency: The Karolinska Experience. <i>Transplantation</i> , 2016 , 100, 1356-62	1.8	22
313	Improved overall survival for pediatric patients undergoing allogeneic hematopoietic stem cell transplantation - A comparison of the last two decades. <i>Pediatric Transplantation</i> , 2016 , 20, 667-74	1.8	19
312	The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. <i>Haematologica</i> , 2016 , 101, 1426-1433	6.6	41
311	Different Procoagulant Activity of Therapeutic Mesenchymal Stromal Cells Derived from Bone Marrow and Placental Decidua. <i>Stem Cells and Development</i> , 2015 , 24, 2269-79	4.4	64
310	Mesenchymal stem (stromal) cells for treatment of acute respiratory distress syndrome. <i>Lancet Respiratory Medicine,the</i> , 2015 , 3, e12	35.1	6
309	Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1589-96	4.7	31
308	Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. <i>British Journal of Haematology</i> , 2015 , 169, 711-8	4.5	40
307	Xeno-immunosuppressive properties of human decidual stromal cells in mouse models of alloreactivity in vitro and in vivo. <i>Cytotherapy</i> , 2015 , 17, 1732-45	4.8	12
306	Treatment of severe chronic graft-versus-host disease with decidual stromal cells and tracing with (111)indium radiolabeling. <i>Stem Cells and Development</i> , 2015 , 24, 253-63	4.4	32
305	Quality of the hematopoietic stem cell graft affects the clinical outcome of allogeneic stem cell transplantation. <i>Transfusion</i> , 2015 , 55, 2339-50	2.9	13
304	Bone marrow aspiration technique has deteriorated in recent years. <i>Bone Marrow Transplantation</i> , 2015 , 50, 1007-9	4.4	17
303	Effect of Total Nucleated and CD34(+) Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 889-93	4.7	67
302	Immunogenicity of decidual stromal cells in an epidermolysis bullosa patient and in allogeneic hematopoietic stem cell transplantation patients. <i>Stem Cells and Development</i> , 2015 , 24, 1471-82	4.4	17
301	The relationship between oral mucositis and levels of pro-inflammatory cytokines in serum and in gingival crevicular fluid in allogeneic stem cell recipients. <i>Supportive Care in Cancer</i> , 2015 , 23, 1749-57	3.9	9
300	Stromal cells-are they really useful for GVHD?. <i>Bone Marrow Transplantation</i> , 2014 , 49, 737-43	4.4	30

299	Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 135-8	4.7	39
298	Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 264-71	4.7	28
297	Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1777-84	4.7	40
296	Reduced plasma levels of soluble interleukin-7 receptor during graft-versus-host disease (GVHD) in children and adults. <i>BMC Immunology</i> , 2014 , 15, 25	3.7	11
295	Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients. <i>Supportive Care in Cancer</i> , 2014 , 22, 2133-40	3.9	21
294	Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 202-8	4.7	27
293	Posaconazole concentrations in human tissues after allogeneic stem cell transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 4941-3	5.9	16
292	Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1418-25	4.7	33
291	Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014 , 99, 346-52	6.6	114
290	HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation. <i>Blood</i> , 2014 , 124, 3996-4003	2.2	111
289	Twenty-year follow-up of a randomized trial comparing intraosseous and i.v. BM transplantation. <i>Bone Marrow Transplantation</i> , 2014 , 49, 1541-2	4.4	5
288	Hematopoietic SCT: a useful treatment for late metachromatic leukodystrophy. <i>Bone Marrow Transplantation</i> , 2014 , 49, 1046-51	4.4	33
287	Superselective intra-arterial umbilical cord blood administration to BM in experimental animals. <i>Bone Marrow Transplantation</i> , 2014 , 49, 1486-91	4.4	2
286	Home care during neutropenia after allogeneic hematopoietic stem cell transplantation in children and adolescents is safe and may be more advantageous than isolation in hospital. <i>Pediatric Transplantation</i> , 2014 , 18, 398-404	1.8	7
285	TCR+CD4-CD8- T cells in antigen-specific MHC class I-restricted T-cell responses after allogeneic hematopoietic stem cell transplantation. <i>Journal of Immunotherapy</i> , 2014 , 37, 416-25	5	7
284	Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia?. <i>Transplantation</i> , 2014 , 98, 569-77	1.8	8
283	Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. <i>Bone Marrow Transplantation</i> , 2014 , 49, 168-73	4.4	181
282	Pre-Transplant C-Reactive Protein (CRP), Ferritin and Albumin As Biomarkers to Predict Transplant Related Mortality (TRM) after Allogeneic Hematopoietic Cell Transplant (HCT). <i>Blood</i> , 2014 , 124, 422-422	2.2	5

281	Survival after T-Cell Replete Haplo-Identical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. <i>Blood</i> , 2014 , 124, 679-679	2.2	3
280	Human C1q Deficiency and Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014 , 124, 5922-5922		
279	Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 314-20	4.7	19
278	Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease. <i>Stem Cells</i> , 2013 , 31, 592-601	5.8	73
277	Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus-Host Disease and Graft Failure After Hematopoietic Stem Cell Transplantation and Future Challenges 2013 , 173-205		2
276	Decidual stromal cells promote regulatory T cells and suppress alloreactivity in a cell contact-dependent manner. <i>Stem Cells and Development</i> , 2013 , 22, 2596-605	4.4	54
275	Graft failure in the modern era of allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2013 , 48, 537-43	4.4	163
274	Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning. <i>Pediatric Transplantation</i> , 2013 , 17, 285-93	1.8	11
273	A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation. <i>Journal of Internal Medicine</i> , 2013 , 274, 153-62	10.8	33
272	A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. <i>Clinical Transplantation</i> , 2013 , 27, E368-74	3.8	41
271	Graft Failure In Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013 , 122, 4559-4559	2.2	
270	Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients. <i>Journal of Internal Medicine</i> , 2012 , 272, 472-83	10.8	29
269	Disturbances in dental development and craniofacial growth in children treated with hematopoietic stem cell transplantation. <i>Orthodontics and Craniofacial Research</i> , 2012 , 15, 21-9	3	19
268	Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation. <i>European Journal of Haematology</i> , 2012 , 89, 220-7	3.8	57
267	Treatment of severe acute graft-versus-host disease with mesenchymal stromal cells: a comparison with non-MSD treated patients. <i>International Journal of Hematology</i> , 2012 , 96, 822-4	2.3	32
266	Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. <i>Lancet Oncology</i> , 2012 , 13, 366-74	21.7	230
265	Is graft-versus-leukemia more effective using reduced-intensity conditioning compared with myeloablative conditioning?. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1615-7	4.7	1
264	Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 557-64	4.7	237

263	Are therapeutic human mesenchymal stromal cells compatible with human blood?. <i>Stem Cells</i> , 2012 , 30, 1565-74	5.8	212
262	Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. <i>Stem Cells</i> , 2012 , 30, 1575-8	5.8	368
261	Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution. <i>Medical Oncology</i> , 2012 , 29, 2348-58	3.7	3
260	Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic bone marrow transplantation. <i>British Journal of Haematology</i> , 2012 , 157, 220-9	4.5	5
259	Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro. <i>Clinical and Experimental Immunology</i> , 2012 , 167, 543-55	6.2	74
258	Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation. <i>Bone Marrow Transplantation</i> , 2012 , 47, 706-15	4.4	38
257	Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. <i>Bone Marrow Transplantation</i> , 2012 , 47, 831-7	4.4	28
256	Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. <i>Bone Marrow Transplantation</i> , 2012 , 47, 203-11	4.4	212
255	Factors with an impact on chimerism development and long-term survival after umbilical cord blood transplantation. <i>Transplantation</i> , 2012 , 94, 1066-74	1.8	19
254	Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2011 , 46, 200-7	4.4	143
253	Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages. <i>Best Practice and Research in Clinical Haematology</i> , 2011 , 24, 65-72	4.2	72
252	One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 410-8	4.7	44
251	Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1688-97	4.7	106
250	Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses. <i>PLoS ONE</i> , 2011 , 6, e21703	3.7	101
249	Second allogeneic hematopoietic stem cell transplantation: a treatment for graft failure. <i>Clinical Transplantation</i> , 2011 , 25, E68-76	3.8	30
248	Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI. <i>Oral Diseases</i> , 2011 , 17, 670-6	3.5	8
247	Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders. <i>European Journal of Haematology</i> , 2011 , 87, 503-9	3.8	19
246	Xerostomia in children and adolescents after stem cell transplantation conditioned with total body irradiation or busulfan. <i>Oral Oncology</i> , 2011 , 47, 915-9	4.4	8

245	Hematopoietic stem cell transplantation in severe congenital neutropenia. <i>Pediatric Blood and Cancer</i> , 2011 , 56, 444-51	3	30
244	Pooled MSCs for treatment of severe hemorrhage. <i>Bone Marrow Transplantation</i> , 2011 , 46, 1158-60	4.4	19
243	Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1728-37	4.7	20
242	Granulocyte colony-stimulating factor induced acute and chronic graft-versus-host disease. <i>Transplantation</i> , 2010 , 90, 1022-9	1.8	25
241	Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). <i>Transplantation</i> , 2010 , 90, 124-6	1.8	57
240	Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. <i>Haematologica</i> , 2010 , 95, 2119-25	6.6	103
239	Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. <i>Blood</i> , 2010 , 116, 4007-15	2.2	94
238	GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants. <i>European Journal of Haematology</i> , 2010 , 84, 323-31	3.8	13
237	Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4570-7	2.2	211
236	The allogeneic graft-versus-cancer effect. <i>British Journal of Haematology</i> , 2009 , 147, 614-33	4.5	117
235	A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT. <i>Bone Marrow Transplantation</i> , 2009 , 43, 553-61	4.4	92
234	Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 326-35	4.7	24
233	Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1108-15	4.7	87
232	Mesenchymal stromal cells as first-line treatment of graft failure after hematopoietic stem cell transplantation. <i>Stem Cells and Development</i> , 2009 , 18, 1243-6	4.4	14
231	Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells. <i>Cytotherapy</i> , 2009 , 11, 129-36	4.8	60
230	HSCT recipients have specific tolerance to MSC but not to the MSC donor. <i>Journal of Immunotherapy</i> , 2009 , 32, 755-64	5	47
229	Increased frequency and responsiveness of PSA-specific T cells after allogeneic hematopoietic stem-cell transplantation. <i>Transplantation</i> , 2009 , 87, 467-72	1.8	2
228	The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. <i>Blood</i> , 2009 , 113, 3110-8	2.2	136

227	Comparison of Outcomes After Unrelated Cord Blood Transplantation and Matched Unrelated Donor RIC Transplantation for Lymphoid Malignancies - A Eurocord-Netcord Group/ Lymphoma Working Party and Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Study. <i>Blood</i> , 2009 , 114, 662-669	2.2	3
226	Comparison of Busulfan and Cyclophosphamide (Bu-Cy)-Based Standard Myeloablative Conditioning (MAC) Vs. Fludarabine and Busulfan (Flu-Bu)-Based Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) Patients in First Complete Remission (CR1) Aged >40 Years: a	2.2	
225	Long-Term Survival and Late Deaths After Hematopoietic Stem Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism.. <i>Blood</i> , 2009 , 114, 3320-3320	2.2	3364
224	Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Myeloma (MM) - Chronic Graft Versus Host Disease (GVHD) is Associated with Lower Risk of Relapse and Superior Progression Free Survival (PFS) - A CIBMTR Analysis.. <i>Blood</i> , 2009 , 114, 53-53	2.2	
223	Unrelated cord blood and mismatched unrelated volunteer donor transplants, two alternatives in patients who lack an HLA-identical donor. <i>Bone Marrow Transplantation</i> , 2008 , 42, 643-8	4.4	31
222	Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study. <i>Bone Marrow Transplantation</i> , 2008 , 41, 399-405	4.4	27
221	BK-viruria and haemorrhagic cystitis are more frequent in allogeneic haematopoietic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts. <i>Bone Marrow Transplantation</i> , 2008 , 41, 737-42	4.4	65
220	Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: a single centre study. <i>Tissue Antigens</i> , 2008 , 72, 549-58		17
219	Genomic tissue typing and optimal antithymocyte globuline dose using unrelated donors results in similar survival and relapse as HLA-identical siblings in haematopoietic stem-cell transplantation for leukaemia. <i>European Journal of Haematology</i> , 2008 , 80, 419-28	3.8	16
218	A Phase 3, Randomized, Placebo-controlled Trial of Filgrastim in Patients with Haematological Malignancies Undergoing Matched-related Allogeneic Bone Marrow Transplantation. <i>Archives of Drug Information</i> , 2008 , 1, 89-96		11
217	Graft failure after allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 165-70	4.7	133
216	Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. <i>Lancet, The</i> , 2008 , 371, 1579-86	4.0	2135
215	No increased trapping of multipotent mesenchymal stromal cells in bone marrow filters compared with other bone marrow cells. <i>Cytotherapy</i> , 2008 , 10, 238-42	4.8	7
214	Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5728-34	2.2	135
213	Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses. <i>Blood</i> , 2008 , 112, 532-41	2.2	136
212	Case-control comparison of at-home and hospital care for allogeneic hematopoietic stem-cell transplantation: the role of oral nutrition. <i>Transplantation</i> , 2008 , 85, 1000-7	1.8	33
211	Similar Outcomes Using Myeloablative Versus Reduced Intensity and Non-Myeloablative Allogeneic Transplant Preparative Regimens for AML or MDS: From the Center for International Blood and Marrow Transplant Research. <i>Blood</i> , 2008 , 112, 348-348	2.2	9
210	Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases. <i>Bone Marrow Transplantation</i> , 2007 , 39, 383-8	4.4	17

209	Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. <i>Leukemia</i> , 2007 , 21, 1733-8	10.7	366
208	Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon. <i>Leukemia</i> , 2007 , 21, 2271-6	10.7	168
207	Hemorrhagic cystitis: a retrospective single-center survey. <i>Clinical Transplantation</i> , 2007 , 21, 659-67	3.8	45
206	Immunomodulation by mesenchymal stem cells and clinical experience. <i>Journal of Internal Medicine</i> , 2007 , 262, 509-25	10.8	570
205	Mesenchymal stem cells stimulate antibody secretion in human B cells. <i>Scandinavian Journal of Immunology</i> , 2007 , 65, 336-43	3.4	226
204	Relapse of preB-ALL after rituximab treatment for chronic graft versus host disease: implications for its use?. <i>Medical Oncology</i> , 2007 , 24, 354-6	3.7	5
203	The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. <i>Blood</i> , 2007 , 110, 4560-6	2.2	149
202	Generation of immunosuppressive mesenchymal stem cells in allogeneic human serum. <i>Transplantation</i> , 2007 , 84, 1055-9	1.8	52
201	Similar outcome after unrelated allogeneic peripheral blood stem cell transplantation compared with bone marrow in children and adolescents. <i>Transplantation</i> , 2007 , 84, 551-4	1.8	16
200	Immunotherapy by allogeneic stem cell transplantation. <i>Advances in Cancer Research</i> , 2007 , 97, 25-60	5.9	26
199	Recent Decrease in Acute GVHD and Increased Relapse in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants.. <i>Blood</i> , 2007 , 110, 1081-1081	2.2	
198	Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe. <i>Annals of Oncology</i> , 2006 , 17, 1134-40	10.3	72
197	Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. <i>Transplantation</i> , 2006 , 81, 1390-7	1.8	896
196	Mesenchymal stem cells combined with cyclosporine inhibits cytotoxic T cells. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 693-4	4.7	13
195	KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 828-36	4.7	173
194	Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2006 , 107, 1712-6	2.2	74
193	Costs of allogeneic hematopoietic stem cell transplantation. <i>Transplantation</i> , 2006 , 82, 147-53	1.8	42
192	Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center. <i>Transplantation</i> , 2006 , 81, 718-25	1.8	51

191	Treatment costs and survival in patients with grades III-IV acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation during three decades. <i>Transplantation</i> , 2006 , 81, 1600-3	1.8	16
190	Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. <i>Bone Marrow Transplantation</i> , 2006 , 37, 1051-9	4.4	71
189	Myeloablative conditioning for hematopoietic stem-cell transplantation in patients with non-malignant diseases. <i>Bone Marrow Transplantation</i> , 2006 , 38, 321-2	4.4	2
188	Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. <i>Current Opinion in Immunology</i> , 2006 , 18, 586-91	7.8	185
187	Mesenchymal Stem Cells for Treatment of Severe Acute Graft-Versus-Host Disease.. <i>Blood</i> , 2006 , 108, 2918-2918	2.2	2
186	Mesenchymal Stem Cells for Treatment of Severe Acute Graft-Versus-Host Disease.. <i>Blood</i> , 2006 , 108, 5304-5304	2.2	8
185	The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen. <i>Haematologica</i> , 2006 , 91, 401-4	6.6	79
184	The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2006 , 91, 1059-67	6.6	78
183	Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. <i>Experimental Cell Research</i> , 2005 , 305, 33-41	4.2	409
182	Introduction to graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 17-20	4.7	8
181	Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 321-34	4.7	375
180	Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. <i>Transplantation</i> , 2005 , 79, 1607-14	1.8	344
179	Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. <i>Blood</i> , 2005 , 105, 548-51	2.2	62
178	A prospective randomized trial of a prophylactic platelet transfusion trigger of 10×10^9 per L versus 30×10^9 per L in allogeneic hematopoietic progenitor cell transplant recipients. <i>Transfusion</i> , 2005 , 45, 1064-72	2.9	83
177	Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2005 , 36, 511-6	4.4	31
176	Allogeneic hematopoietic stem cell transplantation: state of the art and new perspectives. <i>Apms</i> , 2005 , 113, 813-30	3.4	55
175	Fatal Infectious Complications Developing Late after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2005 , 106, 3239-3239	2.2	
174	Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2004 , 22, 416-23	2.2	156

173	Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2816-25	2.2	171
172	Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. <i>Journal of Clinical Oncology</i> , 2004 , 22, 1273-80	2.2	215
171	Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 128-34	4.7	41
170	Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 195-203	4.7	42
169	Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. <i>Lancet, The</i> , 2004 , 363, 1439-41	4.0	2237
168	A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation. <i>Transplantation</i> , 2004 , 78, 1014-20	1.8	54
167	No important influence of limited steroid exposure on bone mass during the first year after renal transplantation: a prospective, randomized, multicenter study. <i>Transplantation</i> , 2004 , 78, 101-6	1.8	138
166	Indium-111-labelled donor-lymphocyte infusion by way of hepatic artery and radio-frequency ablation against liver metastases of renal and colon carcinoma after allogeneic hematopoietic stem-cell transplantation. <i>Transplantation</i> , 2004 , 78, 697-703	1.8	12
165	Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation. <i>Transplantation</i> , 2004 , 78, 1081-5	1.8	69
164	Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. <i>Transplantation</i> , 2004 , 78, 122-7	1.8	100
163	Liver transplantation followed by adjuvant nonmyeloablative hemopoietic stem cell transplantation for advanced primary liver cancer in humans. <i>Transplantation</i> , 2003 , 75, 1061-6	1.8	14
162	Transplantation of embryonic stem cells: possibilities and challenges. <i>Transplantation</i> , 2003 , 76, 1011-2	1.8	7
161	Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. <i>Transplantation</i> , 2003 , 76, 1208-13	1.8	491
160	HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. <i>Experimental Hematology</i> , 2003 , 31, 890-6	3.1	1336
159	Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. <i>Tissue Antigens</i> , 2003 , 62, 243-50		66
158	Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. <i>Scandinavian Journal of Immunology</i> , 2003 , 57, 11-20	3.4	1141
157	Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. <i>British Journal of Haematology</i> , 2003 , 121, 874-85	4.5	71
156	Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2003 , 122, 788-94	4.5	38

155	Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow. <i>Bone Marrow Transplantation</i> , 2003 , 31, 23-9	4.4	43
154	Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. <i>Bone Marrow Transplantation</i> , 2003 , 31, 253-61	4.4	120
153	G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. <i>Bone Marrow Transplantation</i> , 2003 , 32, 217-23	4.4	50
152	The graft-versus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors. <i>Bone Marrow Transplantation</i> , 2002 , 30, 761-8	4.4	21
151	Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors. <i>Bone Marrow Transplantation</i> , 2002 , 29, 391-7	4.4	70
150	Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European survey. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4324-30	2.2	60
149	Ten years' experience with liposomal amphotericin B in transplant recipients at Huddinge University Hospital. <i>Journal of Antimicrobial Chemotherapy</i> , 2002 , 49 Suppl 1, 51-5	5.1	6
148	Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. <i>Blood</i> , 2002 , 100, 406-14	2.2	445
147	Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. <i>Blood</i> , 2002 , 100, 1977-83	2.2	197
146	Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. <i>Blood</i> , 2002 , 100, 4317-24	2.2	122
145	Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4655-64	2.2	129
144	No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. <i>Blood</i> , 2001 , 98, 1739-45	2.2	99
143	The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia. <i>Blood</i> , 2001 , 98, 1982-4	2.2	78
142	Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. <i>Clinical Transplantation</i> , 2001 , 15, 147-53	3.8	66
141	A graft-versus-colonic cancer effect of allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2001 , 28, 1161-6	4.4	25
140	Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation. <i>Leukemia</i> , 2001 , 15, 1976-85	10.7	103
139	The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2001 , 7, 31-8	4.7	45
138	No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3406-14	2.2	81

137	T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. <i>Transplantation</i> , 2001 , 71, 433-9	1.8	78
136	The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2000 , 25, 1053-8	4.4	27
135	Is it safe to treat allogeneic stem cell transplant recipients at home during the pancytopenic phase? A pilot trial. <i>Bone Marrow Transplantation</i> , 2000 , 26, 1057-60	4.4	21
134	Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease. <i>Leukemia</i> , 2000 , 14, 247-54	10.7	57
133	Response to Dr furebring. <i>Bone Marrow Transplantation</i> , 2000 , 25, 342-3	4.4	1
132	Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 2000 , 25, 843-51	4.4	63
131	Faster engraftment of neutrophils and platelets with peripheral blood stem cells from unrelated donors: a comparison with marrow transplantation. <i>Bone Marrow Transplantation</i> , 2000 , 25 Suppl 2, S6-8	4.4	20
130	N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2000 , 25, 993-6	4.4	59
129	High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. <i>British Journal of Haematology</i> , 2000 , 111, 774-781	4.5	3
128	Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. <i>Blood</i> , 2000 , 95, 807-814	2.2	288
127	Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?. <i>British Journal of Haematology</i> , 2000 , 111, 1130-7	4.5	52
126	Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer. <i>Transplantation</i> , 2000 , 69, 2043-8	1.8	27
125	Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. <i>Blood</i> , 2000 , 95, 3323-7	2.2	66
124	Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2000 , 95, 3702-9	2.2	352
123	Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 1999 , 24, 389-96	4.4	36
122	Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia. <i>Bone Marrow Transplantation</i> , 1999 , 24, 629-35	4.4	45
121	Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1999 , 24, 823-30	4.4	113
120	A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1999 , 24, 831-6	4.4	41

119	Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. <i>Blood</i> , 1999 , 93, 2196-201	2.2	36
118	Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. <i>Blood</i> , 1999 , 94, 455-64	2.2	26
117	Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age. <i>Bone Marrow Transplantation</i> , 1998 , 21, 43-9	4.4	24
116	Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 1998 , 21, 995-1003	4.4	202
115	Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. <i>Bone Marrow Transplantation</i> , 1998 , 22, 795-800	4.4	70
114	Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. <i>Bone Marrow Transplantation</i> , 1998 , 22, 755-61	4.4	146
113	Increased serum concentrations of interleukin-2 receptor in the first trimester in women who later developed severe preeclampsia. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1998 , 77, 591-3	3.8	27
112	Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies. <i>Transplantation</i> , 1998 , 66, 620-5	1.8	56
111	Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. <i>Transplantation</i> , 1998 , 66, 1330-4	1.8	129
110	Faster engraftment of peripheral blood progenitor cells compared to bone marrow from unrelated donors. <i>Bone Marrow Transplantation</i> , 1998 , 21 Suppl 3, S81-4	4.4	1
109	Serum levels of cytokines after bone marrow transplantation: increased IL-8 levels during severe veno-occlusive disease of the liver. <i>European Journal of Haematology</i> , 1997 , 59, 254-62	3.8	30
108	Allogeneic bone marrow transplantation for hematological malignancies--controversies and recent advances. <i>Acta Oncologica</i> , 1997 , 36, 549-64	3.2	41
107	Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine. The Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Transplantation Proceedings</i> , 1997 , 29, 733-4	1.1	25
106	Transplantation with unrelated bone marrow in leukemic patients above 40 years of age. <i>Transplantation Proceedings</i> , 1997 , 29, 3145-6	1.1	1
105	Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Acute Leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) and the International Marrow Unrelated Search and Transplant (IMUST) Study. <i>Bone Marrow Transplantation</i> , 1997 , 19, 963-8	4.4	41
104	Bone marrow transplantation using unrelated donors for haematological malignancies. <i>Medical Oncology</i> , 1997 , 14, 11-22	3.7	18
103	Generation of cytokines in red cell concentrates during storage is prevented by prestorage white cell reduction. <i>Transfusion</i> , 1997 , 37, 678-84	2.9	134
102	Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation. <i>Pediatric Transplantation</i> , 1997 , 1, 124-9	1.8	19

101	The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). <i>Leukemia and Lymphoma</i> , 1996 , 24, 71-9	1.9	80
100	Graft-versus-myeloma effect. <i>Lancet, The</i> , 1996 , 348, 346	4.0	67
99	A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>British Journal of Haematology</i> , 1996 , 93, 637-45	4.5	125
98	Transplantation of peripheral blood progenitor cells from unrelated donors. <i>Bone Marrow Transplantation</i> , 1996 , 17 Suppl 2, S62-4	4.4	1
97	Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 1996 , 18, 921-9	4.4	84
96	Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. <i>Blood</i> , 1995 , 86, 1614-1618	2.2	69
95	Lipid formulations of amphotericin B. Less toxicity but at what economic cost?. <i>Drug Safety</i> , 1995 , 13, 207-18	5.1	38
94	Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. <i>Lancet, The</i> , 1995 , 345, 1398-402	4.0	229
93	Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. <i>Bone Marrow Transplantation</i> , 1995 , 15, 619-25	4.4	118
92	Ten years experience of bone marrow transplantation for Gaucher disease. <i>Transplantation</i> , 1995 , 59, 864-70	1.8	34
91	Risk factors for septicemia during aplastic period after allogeneic bone marrow transplantation. <i>Transplantation Proceedings</i> , 1995 , 27, 3530	1.1	5
90	INCREASED LEVELS OF SOLUBLE INTERLEUKIN-2 RECEPTOR IN VENO-OCCLUSIVE DISEASE OF THE LIVER AFTER ALLOGENIC BONE MARROW TRANSPLANTATION. <i>Transplantation</i> , 1995 , 60, 1293-1298	1.8	19
89	Transplantation with peripheral blood stem cells from unrelated donors without serious graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 1995 , 16, 856-7	4.4	8
88	A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. <i>Blood</i> , 1994 , 83, 2723-2730	2.2	297
87	Busulfan bioavailability. <i>Blood</i> , 1994 , 84, 2144-2150	2.2	175
86	Infection of donor lymphocytes with human T lymphotropic virus type 1 (HTLV-I) following allogeneic bone marrow transplantation for HTLV-I positive adult T-cell leukaemia. <i>British Journal of Haematology</i> , 1994 , 88, 403-5	4.5	44
85	Craniomandibular dysfunction in children treated with total-body irradiation and bone marrow transplantation. <i>Acta Odontologica Scandinavica</i> , 1994 , 52, 99-105	2.2	25
84	Identical-twin bone marrow transplants for leukemia. <i>Annals of Internal Medicine</i> , 1994 , 120, 646-52	8	210

83	Long-term follow-up of a randomized trial comparing T cell depletion with a combination of methotrexate and cyclosporine in adult leukemic marrow transplant recipients. <i>Transplantation</i> , 1994 , 58, 887-91	1.8	24
82	Establishment of a tissue bank for fetal stem cell transplantation. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1994 , 73, 385-8	3.8	34
81	Safety of liposomal amphotericin B (AmBisome) in 187 transplant recipients treated with cyclosporin. <i>Bone Marrow Transplantation</i> , 1994 , 14 Suppl 5, S10-4	4.4	13
80	A randomized trial comparing busulfan vs total body irradiation in allogeneic marrow transplant recipients with hematological malignancies. <i>Transplantation Proceedings</i> , 1994 , 26, 1831-2	1.1	8
79	High cure rate of invasive fungal infections in immunocompromised children using ambisome. <i>Transplantation Proceedings</i> , 1994 , 26, 175-7	1.1	8
78	A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. <i>Blood</i> , 1994 , 83, 2723-30	2.2	59
77	A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. <i>Blood</i> , 1994 , 83, 2723-2730	2.2	5
76	Busulfan bioavailability. <i>Blood</i> , 1994 , 84, 2144-2150	2.2	2
75	Liposomal amphotericin B (AmBisome) treatment of invasive fungal infections in immunocompromised children. <i>Mycoses</i> , 1993 , 36, 187-92	5.2	19
74	Increased risk of relapse in patients with chronic myelogenous leukemia given T-cell depleted marrow compared to methotrexate combined with cyclosporin or monotherapy for the prevention of graft-versus-host disease. <i>European Journal of Haematology</i> , 1993 , 50, 269-74	3.8	19
73	Management of graft-versus-host disease. <i>European Journal of Haematology</i> , 1993 , 51, 1-12	3.8	21
72	Outcome after allogeneic bone marrow transplant for leukemia in older adults. <i>JAMA - Journal of the American Medical Association</i> , 1993 , 270, 57-60	27.4	107
71	Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?. <i>Blood</i> , 1993 , 81, 1094-1101	2.2	146
70	Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation. <i>British Journal of Haematology</i> , 1993 , 83, 118-24	4.5	72
69	Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?. <i>Blood</i> , 1993 , 81, 1094-101	2.2	29
68	Decreased transplant-related complications and improved leukemia-free survival in adults receiving methotrexate combined with cyclosporin compared with either agent alone for prevention of graft-versus-host disease. Advisory Committee of the International Bone Marrow Transplant Registry. <i>Transplantation Proceedings</i> , 1993 , 25, 1241-2	1.1	2
67	Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?. <i>Blood</i> , 1993 , 81, 1094-1101	2.2	4
66	Outcome after allogeneic bone marrow transplant for leukemia in older adults. <i>JAMA - Journal of the American Medical Association</i> , 1993 , 270, 57-60	27.4	106

65	Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients. <i>Scandinavian Journal of Infectious Diseases</i> , 1992 , 24, 143-50		40
64	Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? [see comments]. <i>Blood</i> , 1992 , 79, 2771-2774	2.2	42
63	Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. <i>Blood</i> , 1992 , 80, 1090-1093	2.2	146
62	Alterations in taste acuity associated with allogeneic bone marrow transplantation. <i>Journal of Oral Pathology and Medicine</i> , 1992 , 21, 33-7	3.3	56
61	Correlation of pretransplant viral serology and complications of bone marrow transplantation. <i>Annals of Hematology</i> , 1992 , 64 Suppl, A143-7	3	2
60	Allogeneic bone marrow transplantation: the Huddinge experience. <i>Transplantation Proceedings</i> , 1992 , 24, 371-3	1.1	1
59	Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings. <i>Bone Marrow Transplantation</i> , 1992 , 9, 19-25	4.4	33
58	Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? [see comments]. <i>Blood</i> , 1992 , 79, 2771-2774	2.2	38
57	Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. <i>Blood</i> , 1992 , 80, 1090-1093	2.2	109
56	Simultaneously presenting aplastic anaemia and Hodgkin's disease successfully treated with allogeneic bone marrow transplantation. <i>European Journal of Haematology</i> , 1991 , 46, 314-6	3.8	2
55	Craniofacial growth in bone marrow transplant recipients treated with growth hormone after total body irradiation. <i>European Journal of Oral Sciences</i> , 1991 , 99, 44-7	2.3	2
54	Isoamylase levels in bone marrow transplant patients are affected by total body irradiation and not by graft-versus-host disease. <i>Transplant International</i> , 1991 , 4, 96-98	3	3
53	Serum levels of alpha-1 microglobulin and beta-2 microglobulin in bone marrow transplant recipients treated with cyclosporin A. <i>Transplant International</i> , 1991 , 4, 146-150	3	6
52	Variables predicting oral mucosal lesions in allogeneic bone marrow recipients. <i>Head and Neck</i> , 1991 , 13, 224-9	4.2	18
51	Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. <i>Journal of Antimicrobial Chemotherapy</i> , 1991 , 28 Suppl B, 73-82	5.1	245
50	Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. <i>Bone Marrow Transplantation</i> , 1991 , 7, 113-9	4.4	40
49	Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. <i>Bone Marrow Transplantation</i> , 1991 , 7, 221-6	4.4	63
48	Clinical and biochemical outcome of marrow transplantation for Gaucher disease of the Norrbottnian type. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1990 , 79, 680-5	3.1	44

47	Graft-versus-leukemia reactions after bone marrow transplantation. <i>Blood</i> , 1990 , 75, 555-562	2.2	2182
46	Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. <i>Blood</i> , 1990 , 75, 2459-2464	2.2	276
45	Allogeneic bone marrow transplantations at Huddinge Hospital and strategies to improve survival. <i>Clinical Transplants</i> , 1990 , 175-87		1
44	A role of herpes virus serology for the development of acute graft-versus-host disease. Leukaemia Working Party of the European Group for Bone Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 1990 , 5, 321-6	4.4	30
43	Graft-versus-leukemia reactions after bone marrow transplantation. <i>Blood</i> , 1990 , 75, 555-62	2.2	542
42	Bone marrow transplantation for metabolic disorders at Huddinge Hospital. <i>Transplantation Proceedings</i> , 1990 , 22, 198-202	1.1	16
41	Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. <i>Blood</i> , 1990 , 75, 2459-64	2.2	59
40	Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. <i>Blood</i> , 1990 , 75, 2459-2464	2.2	4
39	Graft-versus-leukemia reactions after bone marrow transplantation. <i>Blood</i> , 1990 , 75, 555-562	2.2	38
38	Serum levels of alpha-1 microglobulin in recipients of renal allografts. <i>Transplant International</i> , 1989 , 2, 23-26	3	5
37	Immunodeficiency associated with bone marrow transplantation. <i>Current Opinion in Immunology</i> , 1989 , 1, 497-501	7.8	0
36	Allogeneic bone marrow transplantation versus chemotherapy in children with acute leukemia in Sweden. <i>Pediatric Hematology and Oncology</i> , 1989 , 6, 137-44	1.7	4
35	Oral mucous membrane lesions in children treated with bone marrow transplantation. <i>European Journal of Oral Sciences</i> , 1989 , 97, 268-77	2.3	1
34	Influenza B in transplant patients. <i>Scandinavian Journal of Infectious Diseases</i> , 1989 , 21, 349-50		66
33	Pretransplant herpes virus serology and chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 1989 , 4, 547-52	4.4	13
32	Variables predicting deep fungal infections in bone marrow transplant recipients. <i>Bone Marrow Transplantation</i> , 1989 , 4, 635-41	4.4	67
31	Graft-versus-leukemia reactions in humans. The Advisory Committee of the International Bone Marrow Transplant Registry. <i>Transplantation Proceedings</i> , 1989 , 21, 2989-92	1.1	40
30	Serum levels of alpha-1 microglobulin in recipients of renal allografts. <i>Transplant International</i> , 1989 , 2, 23-6	3	2

29	Long-term follow-up of the first successful bone marrow transplantation in Gaucher disease. <i>Transplantation</i> , 1988 , 46, 66-70	1.8	78
28	Pretransplant herpesvirus serology and acute graft-versus-host disease. <i>Transplantation</i> , 1988 , 46, 548-528		41
27	Allogeneic bone marrow transplantation for leukemia: factors of importance for long-term survival and relapse. <i>Bone Marrow Transplantation</i> , 1988 , 3, 281-90	4.4	21
26	Spontaneous antibody secretion and DNA synthesis in blood lymphocytes increase during acute graft-versus-host disease. <i>Transplantation Proceedings</i> , 1988 , 20, 503-5	1.1	
25	Allogeneic bone marrow transplantation in children at Huddinge Hospital. <i>Transplantation Proceedings</i> , 1988 , 20, 487-90	1.1	
24	Variables predicting bacterial and fungal infections after allogeneic marrow engraftment. <i>Transplantation</i> , 1987 , 43, 393-8	1.8	32
23	Graft-versus-leukaemia activity associated with cytomegalovirus antibody positive bone marrow donors in acute myeloid leukaemia. <i>Lancet, The</i> , 1987 , 1, 456-7	4.0	10
22	Polyclonal antibody secretion during acute graft-versus-host disease. <i>Scandinavian Journal of Immunology</i> , 1987 , 26, 469-76	3.4	2
21	DNA synthesis in human blood mononuclear cells correlates with severity of acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 1987 , 2, 259-69	4.4	3
20	Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group. <i>Bone Marrow Transplantation</i> , 1987 , 2, 299-305	4.4	32
19	Hemorrhagic cystitis--a manifestation of graft versus host disease?. <i>Bone Marrow Transplantation</i> , 1987 , 2, 19-25	4.4	44
18	European experience of bone marrow transplantation for leukemia. <i>Transplantation Proceedings</i> , 1987 , 19, 2600-4	1.1	29
17	Bone marrow transplantation in three patients with multiple myeloma. <i>Acta Medica Scandinavica</i> , 1986 , 219, 523-7		24
16	Reduced risk of recurrent leukaemia in bone marrow transplant recipients after cytomegalovirus infection. <i>British Journal of Haematology</i> , 1986 , 63, 671-9	4.5	57
15	The importance of pre bone marrow transplantation serology in determining subsequent cytomegalovirus infection. An analysis of risk factors. <i>Scandinavian Journal of Infectious Diseases</i> , 1986 , 18, 199-209		33
14	A randomized trial comparing use of cyclosporin and methotrexate for graft-versus-host disease prophylaxis in bone marrow transplant recipients with haematological malignancies. <i>Bone Marrow Transplantation</i> , 1986 , 1, 41-51	4.4	62
13	Faster immunological recovery after bone marrow transplantation in patients without cytomegalovirus infection. <i>Transplantation</i> , 1985 , 39, 377-84	1.8	42
12	Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. <i>Transplantation</i> , 1985 , 40, 39-44	1.8	96

11	Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients. <i>Scandinavian Journal of Infectious Diseases</i> , 1985 , 17, 157-63		97
10	An analysis of factors predisposing to chronic graft-versus-host disease. <i>Experimental Hematology</i> , 1985 , 13, 1062-7	3.1	63
9	Acyclovir prophylaxis in bone marrow transplant recipients. <i>Scandinavian Journal of Infectious Diseases, Supplement</i> , 1985 , 47, 137-44		31
8	Markedly elevated serum IgE levels following allogeneic and syngeneic bone marrow transplantation. <i>Blood</i> , 1983 , 61, 1190-1195	2.2	49
7	Are increased IgE-levels a signal of an acute graft-versus-host reaction?. <i>Immunological Reviews</i> , 1983 , 71, 57-75	11.3	21
6	Markedly elevated serum IgE levels following allogeneic and syngeneic bone marrow transplantation. <i>Blood</i> , 1983 , 61, 1190-5	2.2	7
5	The first infant to survive a generalized BCG infection. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1982 , 71, 161-5	3.1	5
4	Activation of human T and B cells by rabbit anti-human beta 2-microglobulin. <i>Scandinavian Journal of Immunology</i> , 1980 , 11, 121-30	3.4	6
3	Successful treatment with prednisone and graft-versus-host disease in an allogeneic bone-marrow transplant recipient. <i>Scandinavian Journal of Haematology</i> , 1979 , 22, 333-8		10
2	Use of Mitogens for the Functional Characterization of Human Lymphocyte Subpopulations. <i>Scandinavian Journal of Immunology</i> , 1976 , 5, 125-134	3.4	14
1	B-cell mitogenic effects on human lymphocytes of rabbit anti-human beta 2-microglobulin. <i>Scandinavian Journal of Immunology</i> , 1975 , 4, 171-9	3.4	57